| An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6 … S Mostafa, CMJ Kirkpatrick, K Byron, L Sheffield Journal of Neural Transmission 126, 5-18, 2019 | 81 | 2019 |
| Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity D Lesche, S Mostafa, I Everall, C Pantelis, CA Bousman The pharmacogenomics journal 20 (2), 192-201, 2020 | 62 | 2020 |
| Pharmacogenomics in psychiatry–the challenge of cytochrome P450 enzyme phenoconversion and solutions to assist precision dosing S Mostafa, TM Polasek, CA Bousman, DJ Müeller, LJ Sheffield, ... Pharmacogenomics 23 (15), 857-867, 2022 | 23 | 2022 |
| Quantifying the impact of phenoconversion on medications with actionable pharmacogenomic guideline recommendations in an acute aged persons mental health setting S Mostafa, TM Polasek, LJ Sheffield, D Huppert, CMJ Kirkpatrick Frontiers in psychiatry 12, 724170, 2021 | 19 | 2021 |
| Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients CD Jessel, S Mostafa, M Potiriadis, IP Everall, JM Gunn, CA Bousman Pharmacogenetics and Genomics 30 (7), 145-152, 2020 | 19 | 2020 |
| Polysubstance-induced relapse of schizoaffective disorder refractory to high-dose antipsychotic medications: a case report MG Tucker, S Kekulawala, M Kent, S Mostafa, R Harvey Journal of medical case reports 10, 1-7, 2016 | 11 | 2016 |
| Delineating gene–environment effects using virtual twins of patients treated with clozapine S Mostafa, TM Polasek, C Bousman, A Rostami‐Hodjegan, LJ Sheffield, ... CPT: Pharmacometrics & Systems Pharmacology 12 (2), 168-179, 2023 | 9 | 2023 |
| Cytochrome P450-2D6 activity in people with codeine use disorder MRC Daglish, SR Reilly, S Mostafa, C Edwards, TM O’Gorman, JS Hayllar The Pharmacogenomics Journal 23 (6), 195-200, 2023 | 3 | 2023 |
| Consistent terminology for medication-related problems in pharmacogenomic cases TM Polasek, S Mostafa, CMJ Kirkpatrick Journal of Psychiatry and Neuroscience 48 (3), E151-E152, 2023 | 3 | 2023 |
| Virtual twins for model‐informed precision dosing of clozapine in patients with treatment‐resistant schizophrenia S Mostafa, R Rafizadeh, TM Polasek, CA Bousman, A Rostami‐Hodjegan, ... CPT: Pharmacometrics & Systems Pharmacology 13 (3), 424-436, 2024 | 1 | 2024 |
| Indications for pharmacogenomic testing in Australia SL Stocker, C Freeman, RO Day, AA Somogyi, S Mostafa, CMJ Kirkpatrick, ... ASCEPT, 2023 | | 2023 |
| Increased cytochrome P450-2D6 activity in people with codeine use disorders MRC Daglish, JS Hayllar, S Reilly, S Mostafa, CJ Edwards, TM O'Gorman DRUG AND ALCOHOL REVIEW 41, S51-S52, 2022 | | 2022 |
| Pharmacogenomic testing and its future in community pharmacy S Mostafa, D Wright Evaluation 14, 34, 2020 | | 2020 |
| PHARMACOGENOMICS COMES OF AGE-NEW EVIDENCE LEADS TO INTERNATIONAL DRUG-SPECIFIC RECOMMENDATIONS FOR SSRIS AND TRICYCLIC ANTIDEPRESSANTS L Sheffield, S Mostafa, N Puspasari, T Smith, M Goh, B Snyder AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY 51, 103-103, 2017 | | 2017 |
| Polysubstance-induced relapse of schizoaffective disorder refractory to high-dose antipsychotic medications MG Tucker, S Kekulawala, M Kent, S Mostafa, R Harvey | | 2016 |
